The Dow Jones industrial average futures contract rose by 903 points, equivalent to about 4%. S&P 500 futures rose 3.4%, while the Nasdaq 100 futures rose 2.6%.
Gilead shares jumped 14% in post-close trading on Wall Street, after the results of a recent study published in the journal “New England of Medicine” concluded that about two-thirds of (critically ill) patients with Covid-19 who underwent treatment by a company American “Gilead Sciences” improved their condition.
The patients included in the study, from the United States, Europe, Canada, and Japan, underwent a 10-day course of treatment with Ramsizever.
The study monitored the improvement of 68 percent of patients (36 patients) in terms of the need for support devices, 25 patients (47 percent) were discharged from the hospital, and only seven patients (13 percent) died.
The new data is based on the observations of the 61 patients, but it does not give details of any other treatments they underwent. Moreover, data for eight of them are not available.
But the supervisor of this study, Dr. Jonathan Green, said that the results are “optimistic”, yet he cautioned against rushing to interpret the results due to procedures related to the way the experiment was organized and because of the small size of the group that was subjected to it.
And RMDZIVIR is a new antiviral drug that the American company has been testing for about a month, with results expected to be announced in the coming weeks, and researchers in China and the United States are trying it on Covid-19 patients.
No vaccine or drug has yet been officially approved to treat Covid-19, which has killed more than 100,000 people worldwide.